NEW YORK (GenomeWeb News) – Accelr8 today said fiscal second-quarter revenues rose 53 percent as R&D spending decreased 57 percent and losses narrowed 42 percent.
 
Total receipts for the three months ended Jan. 31 increased to $85,000 from 55,000 year over year.
 
More than half the revenues came from license fees, with smaller amounts coming from option fees and from OptiChem sales.
  
R&D spending fell to $250,000 from $570,000 year over year.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.